Bluemtec Q1 2026: Revenue +28.8%, Operating Loss Narrows, Net Profit Turns Positive (Incl. Non-Recurring Gains)
Consolidated Q1 revenue KRW 44.0bn (up 28.8% YoY from KRW 34.2bn); operating loss KRW 0.74bn (improved from FY2025 loss of KRW 1.97bn)
Standalone figures similar: revenue KRW 44.1bn, operating loss KRW 0.73bn, net profit KRW 2.66bn (EPS KRW 79)
Net profit of KRW 2.64bn turned positive (vs. net loss of KRW 1.61bn in Q1 2025), but includes non-recurring gain of KRW 3.79bn from lease asset disposal
Credit rating B+ (NICE, Apr 2025); gearing ratio 36.5%; total borrowings KRW 41.5bn; net debt KRW 27.3bn
Outstanding bonds with warrants (BW) of KRW 18.4bn face value; exercise price KRW 4,613 (below current ~KRW 3,500); potential dilution
Ongoing litigation with Pharmworld: mutual claims of KRW 1.13bn and KRW 0.89bn (first trial)
CEO change: Kim Junsuk newly appointed; new outside director Kim Hyeja appointed